EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma

Yuewei Xu, Sarah Spear, Yurui Ma, Marc P Lorentzen, Michael Gruet, Flora McKinney, Yitao Xu, Chiharu Wickremesinghe, Madelen R Shepherd, Iain McNeish, Hector C Keun, Anke Nijhuis

Cell Reports · 2023

DOI: 10.1016/j.celrep.2023.113307 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2023. Verfasst von Yuewei Xu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery & Cancer, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Antineoplastic Agents, Ovarian Neoplasms. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Imperial College London, China Scholarship Council, Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsOvarian NeoplasmsFemaleHumansAnimalsMicePoly(ADP-ribose) Polymerase InhibitorsBRCA1 ProteinMutationRNA Splicing FactorsRNABRCA2 ProteinNeoplasm Recurrence, LocalRNA SplicingPhthalazinesSulfonamides

Stichwörter der Autor:innen

CP: CancerDNA repairPARP inhibitorRNA splicingcombination therapyhomolougous recombinationovarian cancerovarian high-grade serous carcinoma

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsBRCA1 ProteinRNA Splicing FactorsRNABRCA2 ProteinAntineoplastic AgentsPhthalazinesN-(3-chloro-7-indolyl)-1,4-benzenedisulphonamideSulfonamidesBRCA1 protein, human

Autor:innen und Institutionen

  • Department of Surgery & Cancer, Imperial College London, London, UK.
  • Department of Surgery & Cancer, Imperial College London, London, UK; Ovarian Cancer Action Research Centre, Department of Surgery & Cancer, Imperial College London, London, UK.
  • Department of Surgery & Cancer, Imperial College London, London, UK; Ovarian Cancer Action Research Centre, Department of Surgery & Cancer, Imperial College London, London, UK. Electronic address: h.keun@imperial.ac.uk.
  • Department of Surgery & Cancer, Imperial College London, London, UK; Ovarian Cancer Action Research Centre, Department of Surgery & Cancer, Imperial College London, London, UK. Electronic address: a.nijhuis@imperial.ac.…

Förderung

  • Imperial College London
  • China Scholarship Council
  • Cancer Research UK
  • NIHR Imperial Biomedical Research Centre
  • Ovarian Cancer Action

Zitieren

APA

Xu, Y., Spear, S., Ma, Y., Lorentzen, M. P., Gruet, M., McKinney, F., Xu, Y., Wickremesinghe, C., Shepherd, M. R., McNeish, I., Keun, H. C., & Nijhuis, A. (2023). Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma. Cell Reports. https://doi.org/10.1016/j.celrep.2023.113307

Vancouver

Xu Y, Spear S, Ma Y, Lorentzen MP, Gruet M, McKinney F, et al. Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma. Cell Reports. 2023. doi:10.1016/j.celrep.2023.113307

BibTeX
@article{Xu2023,
  author = {Xu, Yuewei and Spear, Sarah and Ma, Yurui and Lorentzen, Marc P and Gruet, Michael and McKinney, Flora and Xu, Yitao and Wickremesinghe, Chiharu and Shepherd, Madelen R and McNeish, Iain and Keun, Hector C and Nijhuis, Anke},
  title = {Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma},
  journal = {Cell Reports},
  year = {2023},
  doi = {10.1016/j.celrep.2023.113307}
}
Kostenlos starten →